News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

AR-13324-CS208 Japan Phase 2 Study Topline Results

Corporate Presentation - October

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
Conference Call and Webcast Today, November 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Nov. 6, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 5, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 30, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP